Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

Item

http://www.wikidata.org/entity/Q36619557

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

@ast

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

@en

type

Item

label

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

@ast

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

@en

prefLabel

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

@ast

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

@en

P1476

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry

@en

P2093

Charles Tedder

http://www.w3.org/2001/XMLSchema#string

Edward Chu

http://www.w3.org/2001/XMLSchema#string

Hirokazu Mizuguchi

http://www.w3.org/2001/XMLSchema#string

Jabed Seraj

http://www.w3.org/2001/XMLSchema#string

James J Lee

http://www.w3.org/2001/XMLSchema#string

James Nugteren

http://www.w3.org/2001/XMLSchema#string

Jeremy Hague

http://www.w3.org/2001/XMLSchema#string

Jillian Fiejdasz

http://www.w3.org/2001/XMLSchema#string

Kenichiro Yoshida

http://www.w3.org/2001/XMLSchema#string

Laura Pollice

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.

Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients.

A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.

Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

Mass balance studies, with a focus on anticancer drugs.

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.

P2888

s00280-016-2965-2

P304

515-526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-016-2965-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jan H Beumer

P577

2016-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26787503

http://www.w3.org/2001/XMLSchema#string

P932

4767595

http://www.w3.org/2001/XMLSchema#string